跳至主要内容
临床试验/ISRCTN98903916
ISRCTN98903916
已完成
未知

Prospective, comparative, pharmacodynamic study of two topical dosage regimens of a new finasteride formulation (0.25% o.d. and b.i.d.) and oral finasteride (1 mg o.d.) after 7 days multiple dose administration in male volunteers with androgenetic alopecia

Polichem S.A. (Switzerland)0 个研究点目标入组 18 人2012年8月8日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Androgenetic alopecia
发起方
Polichem S.A. (Switzerland)
入组人数
18
状态
已完成
最后更新
9年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2012年8月8日
结束日期
待定
最后更新
9年前
研究类型
Interventional
性别
Male

研究者

发起方
Polichem S.A. (Switzerland)

入排标准

入选标准

  • 1\. Sex \- male
  • 2\. Age: 18\-65 year olds inclusive
  • 3\. Androgenetic alopecia: recession of the frontal hairline and hair loss in the vertex or crown or loss of hair over the frontal and vertex scalp regions, corresponding to at least stage 2 of the Hamilton\-Norwood scale
  • 4\. BMI: 18, TBMI, T30 kg/m2
  • 5\. Vital signs: SBP 100\-139 mmHg, DBP 50\-89 mmHg, HR 50\-90 bpm, measured after 5 min of rest in the sitting position
  • 6\. Full comprehension:
  • 6\.1\. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
  • 6\.2\. Ability to co\-operate with the Investigator and to comply with the requirements of the entire study
  • 7\. Informed consent: signed written informed consent prior to inclusion in the study

排除标准

  • 1\. ECG (12\-leads) (supine position): clinically relevant abnormalities
  • 2\. Physical findings: clinically relevant abnormal physical findings which could interfere with the objectives of the study; in particular, skin damage such as abrasion, hyperkeratosis or any abnormal findings in the scalp
  • 3\. Laboratory analyses: clinically relevant abnormal laboratory values indicative of physical illness
  • 4\. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
  • 5\. Diseases: relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study
  • 6\. Medications: medications, including over the counter (OTC) drugs, for 2 weeks before the start of the study
  • 7\. Investigative drug trials: participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  • 8\. Blood donation: blood donations for 3 months before this study
  • 9\. Drug, alcohol, caffeine, tobacco: history of drug, alcohol \[\>2 drinks/day], caffeine (\>5 cups coffee/tea/day) or tobacco abuse (\<10 cigarettes/day)
  • 10\. Abnormal diets (\<1600 or \>3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study

结局指标

主要结局

未指定

相似试验